SERTRALINE HYDROCHLORIDE | N215133 | ALMATICA PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Lachman Consulting Services, Inc. FDA-2024-P-3567 · 7 docket documents Lachman Consulting Services, Inc. filed this suitability petition on behalf of a client requesting that the FDA declare Sertraline Capsules in 25 mg, 50 mg, and 100 mg strengths suitable for submission as an ANDA under Section 505(j)(2)(C) of the FD&C Act, citing Sertraline Capsules 150 mg and 200 m | Suitability | 2024-07-30 | Denied | Lachman Consulting Services, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$2.69
per ea
Lowest NADAC/Unit
$2.57
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 52427067230SERTRALINE 200 MG CAPSULE | $2.69 | EA | Generic | — | 2026-06-17 |
| 47781096230SERTRALINE 200 MG CAPSULE | $2.69 | EA | Generic | — | 2026-06-17 |
| 47781095130SERTRALINE 150 MG CAPSULE | $2.57 | EA | Generic | — | 2026-06-17 |
| 52427066430SERTRALINE 150 MG CAPSULE | $2.57 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.